Exact Sciences (EXAS) Tops Q1 EPS by 32c; raises guidance

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.42), $0.32 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $602.45 million versus the consensus estimate of $543.29 million.

GUIDANCE:

Exact Sciences sees FY2023 revenue of $2.38-2.42 billion, versus the consensus of $2.299 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• GTA VI to catalyze a multi-year improvement in earnings power for TTWO, BTIG says
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat